Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP, Rizzuto I, Suppiah P, O'Shea D, Patel M, Spiers L, Sukumaran A, Bharwani N, Rockall A, Gabra H, El-Bahrawy M, Wasan H, Leonard R, Habib N, Ghazaly E. Blagden SP, et al. Among authors: ghazaly e. Br J Cancer. 2018 Oct;119(7):815-822. doi: 10.1038/s41416-018-0244-1. Epub 2018 Sep 12. Br J Cancer. 2018. PMID: 30206366 Free PMC article. Clinical Trial.
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
McNamara MG, Bridgewater J, Palmer DH, Faluyi O, Wasan H, Patel A, Ryder WD, Barber S, Gnanaranjan C, Ghazaly E, Evans TRJ, Valle JW. McNamara MG, et al. Among authors: ghazaly e. Oncologist. 2021 Apr;26(4):e669-e678. doi: 10.1002/onco.13598. Epub 2020 Dec 3. Oncologist. 2021. PMID: 33210382 Free PMC article. Clinical Trial.
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW. Allen MD, et al. Among authors: ghazaly e. Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27. Cancer Res. 2014. PMID: 24285724
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM. van Eijkelenburg NKA, et al. Among authors: ghazaly e. Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17. Haematologica. 2018. PMID: 29773602 Free PMC article. Clinical Trial.
Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function.
Ghazaly EA, Miraki-Moud F, Smith P, Gnanaranjan C, Koniali L, Oke A, Saied MH, Petty R, Matthews J, Stronge R, Joel SP, Young BD, Gribben J, Taussig DC. Ghazaly EA, et al. J Biol Chem. 2020 Apr 17;295(16):5496-5508. doi: 10.1074/jbc.RA119.010467. Epub 2020 Mar 11. J Biol Chem. 2020. PMID: 32161116 Free PMC article.
28 results